Iovance Biotherapeutics Inc (NASDAQ:IOVA) Director Wayne P. Rothbaum acquired 921,053 shares of the firm’s stock in a transaction on Tuesday, December 4th. The stock was purchased at an average cost of $10.31 per share, for a total transaction of $9,496,056.43. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of IOVA traded down $0.98 during trading hours on Friday, hitting $8.97. 721,200 shares of the company were exchanged, compared to its average volume of 1,195,639. The firm has a market cap of $1.22 billion, a P/E ratio of -6.36 and a beta of 2.74. Iovance Biotherapeutics Inc has a fifty-two week low of $7.85 and a fifty-two week high of $19.90.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.03). As a group, equities analysts anticipate that Iovance Biotherapeutics Inc will post -1.29 EPS for the current year.

A number of research analysts have commented on the company. BidaskClub raised Iovance Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Iovance Biotherapeutics in a report on Tuesday, September 25th. Zacks Investment Research raised Iovance Biotherapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Wednesday, October 17th. Cowen reaffirmed a “buy” rating on shares of Iovance Biotherapeutics in a report on Tuesday, November 6th. Finally, ValuEngine lowered Iovance Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 6th. One research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $23.75.

Several institutional investors and hedge funds have recently added to or reduced their stakes in IOVA. Trexquant Investment LP acquired a new stake in shares of Iovance Biotherapeutics during the 2nd quarter worth $129,000. Amalgamated Bank acquired a new stake in shares of Iovance Biotherapeutics during the 2nd quarter worth $161,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Iovance Biotherapeutics by 61.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,918 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 5,318 shares in the last quarter. United Services Automobile Association grew its holdings in shares of Iovance Biotherapeutics by 31.0% during the 2nd quarter. United Services Automobile Association now owns 14,493 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 3,431 shares in the last quarter. Finally, Bellevue Group AG acquired a new stake in shares of Iovance Biotherapeutics during the 3rd quarter worth $281,000. 73.46% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Insider Buying: Iovance Biotherapeutics Inc (IOVA) Director Acquires 921,053 Shares of Stock” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/insider-buying-iovance-biotherapeutics-inc-iova-director-acquires-921053-shares-of-stock/2668665.html.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Further Reading: Understanding the different types of bonds

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.